Study: NCT05579769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Description: Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Description: Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation (radiation treatment)
Description: Days -7, -6, -5 and -4 6.2.3 Target Dose 1200 cGy total dose delivered 150 cGy per treatment fraction delivered BID over 4 days with 6 MV photons.~Dose rate should be \< 10 cGy/min in patients treated at extended SSD (450-500 cm) in the TBI couch and will be less than 15 cGy/min in young children and infants treated at extended SSD (200-220 cm) on the floor.~Intra-fraction interval should be 6 hours. Custom posteriorly placed (PA only) partial transmission lung shields (blocks) will be used to reduce the average dose to the lung to approximately 1000 cGy total dose.~An additional 400 cGy supplemental testicular radiation delivered in 2 fractions of 200 cGy delivered for males with lymphoid lineage leukemia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow infusion
Description: Day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow infusion
Description: Day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous